Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas

[1] Melmed S(2009)Acromegaly pathogenesis and treatment J Clin Invest 119 3189-3202

[2] Katznelson L(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951

[3] Laws ER(2019)Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial Acrom Nat Rev Dis Primers 5 20-2990

[4] Melmed S(2008)Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial J Clin Endocrinol Metab 93 2984-666

[5] Molitch ME(2010)A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly Eur J Endocrinol 162 661-868

[6] Murad MH(2007)Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension Clin Endocrinol 66 859-28

[7] Utz A(2010)Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae Pituitary 13 18-539

[8] Wass JA(2010)The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly Eur J Endocrinol 163 531-6295

[9] Colao A(2005)Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance J Clin Endocrinol Metab 90 6290-115

[10] Grasso LFS(2017)Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form Pituitary 20 109-91

[1] Melmed S(2009)Acromegaly pathogenesis and treatment J Clin Invest 119 3189-3202

[2] Katznelson L(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951

[3] Laws ER(2019)Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial Acrom Nat Rev Dis Primers 5 20-2990

[4] Melmed S(2008)Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial J Clin Endocrinol Metab 93 2984-666

[5] Molitch ME(2010)A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly Eur J Endocrinol 162 661-868

[6] Murad MH(2007)Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension Clin Endocrinol 66 859-28

[7] Utz A(2010)Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae Pituitary 13 18-539

[8] Wass JA(2010)The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly Eur J Endocrinol 163 531-6295

[9] Colao A(2005)Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance J Clin Endocrinol Metab 90 6290-115

[10] Grasso LFS(2017)Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form Pituitary 20 109-91